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Objective: Two missense mutations in KCNQ1, an imprinted gene that encodes the
alpha subunit of the voltage-gated potassium channel Kv7.1, cause autosomal dominant 
growth hormone deficiency and maternally inherited gingival fibromatosis. We evaluated 
endocrine features, birth size, and subsequent somatic growth of patients with long QT 
syndrome 1 (LQT1) due to loss-of-function mutations in KCNQ1.
Design: Medical records of 104 patients with LQT1 in a single tertiary care center
between 1995 and 2015 were retrospectively reviewed.
Methods: Clinical and endocrine data of the LQT1 patients were included in the analyses.
results: At birth, patients with a maternally inherited mutation (n = 52) were shorter than 
those with paternal inheritance of the mutation (n = 29) (birth length, −0.70 ± 1.1 SDS 
vs. −0.2 ± 1.0 SDS, P < 0.05). Further analyses showed, however, that only newborns 
(n = 19) of mothers who had received beta blockers during pregnancy were shorter and 
lighter at birth than those with paternal inheritance of the mutation (n = 29) (−0.89 ± 1.0 
SDS vs. −0.20 ± 1.0 SDS, P < 0.05; and 3,173 ± 469 vs. 3,515 ± 466 g, P < 0.05). 
Maternal beta blocker treatment during the pregnancy was also associated with lower
cord blood TSH levels (P = 0.011) and significant catch-up growth during the first year 
of life (Δ0.08 SDS/month, P  =  0.004). Later, childhood growth of the patients was
unremarkable.
conclusion: Loss-of-function mutations in KCNQ1 are not associated with abnormal-
ities in growth, whereas maternal beta blocker use during pregnancy seems to modify
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inTrODUcTiOn
Defects in ion channels are increasingly implicated in endocrine diseases. For example, dys-
functional or inactive K-ATP channel function due to mutations in KIR6.2/SUR1 genes leads 
to congenital hyperinsulinism and/or neonatal diabetes, and defects in potassium channel 
KCNJ18 underlie periodic hypokalemic paralysis (1–3). We recently reported that two specific 
FigUre 1 | Identification and verification process of the patients with long 
QT syndrome 1 (LQT1) due to KCNQ1 mutations at the Children’s Hospital, 
Helsinki University Hospital. Medical records of 104 patients with genetically 
verified LQT1 and growth data were identified. See main text for details. 
*Miscellaneous reasons such as patient’s medical records were not found.
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mutations in KCNQ1, a gene encoding the alpha subunit of a 
voltage-gated K+ channel (Kv7.1), result in a gain-of-function 
in patch clamp analyses and cause pituitary hormone deficiency 
and maternally inherited gingival fibromatosis (4). This finding 
was unexpected, since KCNQ1 is traditionally considered as 
an important regulator of cardiac repolarization rather than 
one of the key regulators of human growth (5). A prelude for 
this possibility was achieved already in 2015, however, when 
Zoledziewska et al. showed that maternally inherited variation 
in KCNQ1 was associated with shorter adult height in the 
Sardinian population, although the mechanism of this finding 
has not been established (6). In other words, there may be 
growth-regulating mechanisms unrelated to growth hormone 
secretion by which KCNQ1 affects height. Indeed, KCNQ1 
is located on chromosome 11p15.5 in a cluster of imprinted 
growth-regulating genes. The KCNQ1 locus contains imprint-
ing control region 2, which regulates the imprinting of nearby 
genes, such as CDKN1C (7). Mutations in this imprinted region 
cause the growth disorders Beckwith–Wiedemann syndrome 
(BWS) and Silver–Russell syndrome (8). BWS, which is char-
acterized by placental and pre- and postnatal overgrowth, is 
occasionally caused by maternally inherited mutations which 
also disrupt KCNQ1 (9).
According to the parental conflict theory, imprinting has 
evolved to serve the conflicting interests of the father and the 
mother; paternally expressed genes promote fetal growth to 
ensure the viability of the present offspring, whereas maternally 
expressed genes restrict fetal growth to preserve the mother’s 
resources to her future offspring (10). Herein, we investigated the 
growth and endocrine features of patient with long QT syndrome 
(LQTS) due to loss-of-function mutations in KCNQ1. We paid 
special attention to the relationship between early growth and 
parent-of-origin of the mutation.
sUBJecTs anD MeThODs
Patients
In this retrospective study, the patients diagnosed with LQTS 
in Helsinki University Central Hospital between 1997 and 2015 
were first identified from the electronic health records by using 
the ICD-10 code I49.8 (other cardiac arrhythmia) which has been 
used for all LQTS patients. From this population, we excluded 
those with an erroneous diagnosis (other cardiac arrhythmia than 
LQTS), other LQTS than LQT1, and those with missing medical 
or growth data (Figure 1). Overall, 104 patients with genetically 
diagnosed LQT1 and representative growth data were followed 
up in the Children’s Hospital from 1997 to 2015, comprising the 
population of this study. Data collected from all LQT1-patients 
included gender, specification of the KCNQ1 gene mutation and 
its inheritance, treatment modalities, and growth data including 
measurements from the birth to the adulthood and parental 
heights. Additionally, all available endocrine data, including the 
laboratory test results and diagnoses were recorded.
Out of the 104 LQT1 patients, 53 (51%) were males and 7 
(6.7%) had been born prematurely. Birth length and weight data 
were available from 81 patients who were born full term; of them, 
29 had inherited the mutation from the father and 52 from the 
mother. Infancy growth data (at least one length measurement 
was available from 82 patients, altogether 287 measurements). 
There were 94 (90%) patients who were recorded to receive beta 
blocker therapy, 8 symptom-free patients had stopped the medi-
cation. The inheritance of KCNQ1 mutation was documented in 
all except 2 patients; 67 patients had inherited the mutation from 
the mother, 33 from the father, and 2 from both parents. The most 
common mutation was c.1766G > A p.(Gly589Asp) (63%). The 
molecular genetic findings are described in Table 1.
statistical analyses
Values are mean (SD) unless otherwise stated. The analyses 
were carried out with the SPSS statistical software for Windows, 
release 22.0 (SPSS, Chicago, IL, USA) and with R® using packages 
lme4 and lmerTest (20–22). Premature infants were excluded. 
The one sample t-test was used for comparing the height SDS 
at different ages with the general population. The independent 
samples t-test was employed in analyzing the effect of paternal/
maternal inheritance on growth. The linear mixed-model was 
used for analyzing the associations between birth length, first 
year growth, beta blocker use during pregnancy and genetic 
features, and for comparing cord blood TSH values between the 
subgroups. To account for the sibship between the patients and 
the differences between the growth of the individuals in the first 
year model, random intercepts, and slopes were fitted for both 
the family and the individual. The effects of the beta blocker use 
during pregnancy combined with the inheritance of the KCNQ1 
mutation were estimated both on birth and per month during 
the first year. The p-values were calculated using Satterthwaite’s 
degrees of freedom approximation. The statistically significant 
level was set to P < 0.05.
informed consent and ethical approval
Since this study is entirely based on health record data, no 
ethical permission was required according to the Finnish Medical 
TaBle 1 | Molecular genetic diagnoses of long QT syndrome 1 (LQT1) patients and the structural and rationalized effects of the mutant proteins.
Mutation type inherited from (n) structural effect rationalization of effect
Mother Father
c.377A > T p.(His126Leu) 1 Perturbation of S1 Interacts with S0
c.683 + 5G > A 1
c.691C > T p.(Arg231Cys) 2 Perturbation of S4 Neutralizes one of the positive charges on S4
c.805G > A p.(Gly269Ser) 2 Perturbation of S5 Steric hindrance with F339 in S6
c.830C > T p.(Ser277Leu) 1 1 Perturbation of S5 Steric hindrance with A302 in S6
c.949G > A p.(Asp317Asn) 2 2 Perturbation of selectivity filter
c.1022C > T p.(Ala341Val) 2 Perturbation of S6 Steric hindrance of S6 kink—helix crossing  
apposing A341 from neighboring S6 (inner gate)
c.1096C > T p.(Arg366Trp) 3 2 Perturbation of pre-helix A: helix A Possible steric hindrance by W causing some degree  
of compromised calmodulin (CaM) association and  
PIP2 binding or gating perturbation (11, 12)
c.1129-2A > G (IVS7-2A > G, FinB) 6 3
c.1331C > T p.(Thr444Met). 1 Intervening loop
c.1552C > T p.(Arg518Ter) 2 Truncation of helix B Predicted abrogation of biosynthesis/assembly (13, 14)
c.1681A > G p.(Arg561Gly) 2 Perturbation of helix C (either coiled 
coil formation or possibly interactor)
Predicted abrogation of biosynthesis/assembly
c.1766G > A p.(Gly589Asp, FinA) 43 22 Perturbation of helix D Trafficking affected. characterized in Wiener et al. (15) 
and Aromolaran et al. (16)
c.1781G > A p.(Arg594Gln) 1 Perturbation of helix D Discussed in Wiener et al. (15)
KCNQ1 deletiona 1
Inheritance pattern was unknown for one patient with FinA and in one with FinB mutation. In addition, two patients had Jervell–Lange–Nielsen syndrome [one patient was 
homozygous for c.1766G > A p.(Gly589Asp) mutation, and another patient was compound-heterozygous for c.1766G > A p.(Gly589Asp) and p.(Tyr171Ter)]. The KCNQ1 
membrane domain has a canonical voltage-gated membrane topology with six transmembrane segments, S1–6. Structural studies have shown that many voltage-gated channels 
have an amphipathic segment called S0 that lies in the plane of the inner membrane leaflet, upstream of S1. S1 through S4 comprises the voltage-sensor, and S5 and S6 comprise 
the pore domain. The intracellular C-terminal domain contains a module (helices A–B) to which CaM binds, guiding channel assembly and gating and an additional module with 
tandem coiled-coils (helices C–D), responsible for tetramerization (15, 17–19).
aDetails of the deletion not available in medical charts.
TaBle 2 | Distributions (mean ± SD) of birth length [in standard deviation scores 
(SDS)] and birth weight in patients with long QT syndrome 1 due to paternally or 
maternally inherited KCNQ1 mutations.
Birth length Birth weight
sDs P grams P
Paternal inheritance (n = 29) −0.20 ± 1.0 3,515 ± 466
Maternal inheritance without beta 
blocker during pregnancy (n = 33)
−0.59 ± 1.1 0.19 3,486 ± 517 0.88
Maternal inheritance and with beta 
blocker during pregnancy (n = 19)
−0.89 ± 1.0 0.017 3,173 ± 469 0.014
The two maternal inheritance subgroups (without beta blocker and with beta blocker 
during pregnancy) were compared to the paternal inheritance group with a random 
effects model.
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Birth length and weight data were available for 81 patients with 
known maternal or paternal inheritance of the mutation. Those 
with maternal inheritance of the KCNQ1 mutation (n  =  52) 
were born significantly shorter than those (n = 29) with paternal 
inheritance (−0.70 ± 1.1 SDS vs. −0.20 ± 1.0 SDS, respectively; 
P = 0.046). There was no significant difference in birth weight 
(3,371 ± 519 vs. 3,515 ± 466 g, respectively; P = NS). When the 
respective comparison was carried out after adjusting for sibship 
in the linear mixed model, the difference in birth length between 
the groups remained significant (data not shown). However, some 
of the patients with maternal inheritance of the KCNQ1 mutation 
(and none of those with paternal inheritance) had been exposed 
to beta blocker treatment prenatally. We, therefore, divided the 
patients into three groups: those with paternal inheritance of 
the mutation (PI, n = 29), maternal inheritance of the mutation 
without mother’s beta blocker treatment (MI/BB−, n = 33), and 
those with beta blocker exposure during pregnancy (MI/BB+, 
n = 19). The patients born in the MI/BB+ group were signifi-
cantly shorter at birth as compared to those with PI, but the birth 
lengths of MI/BB− and PI groups did not differ (Table 2). The 
placental weights (n = 64) did not differ between the MI/BB+, 
MI/BB−, and PI groups (512 ± 85 vs. 577 ± 114 g vs. 575 ± 127 g, 
respectively; P = NS).
Postnatal growth
Growth data during the first year of life was available for 82 
patients and included 287 measurements. During this period, 
patients with maternal inheritance and intrauterine beta blocker 
exposure showed significant catch-up growth (Δ0.08 SDS/
month, P = 0.004), whereas patients with maternal inheritance 
and no such exposure grew steadily (Δ0.01 SDS/month, P = NS) 
(Figure 2). Similarly, length SDS in patients with paternal inherit-
ance did not change significantly during the same period (Δ−0.04 
FigUre 2 | Length standard deviation score (SDS) during the first year of life in long QT syndrome 1 patients. Patients with maternal inheritance of KCNQ1 mutation 
and prenatal beta blocker exposure were shorter than those with paternal inheritance at birth (P < 0.05), and displayed significant catch-up growth during the first 
year of life (Δ0.08 SDS/month, P = 0.004). *No beta blocker exposure during pregnancy; **prenatal beta blocker exposure.
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SDS/month, P = NS). After the first 2 years of life, the patients’ 
mean height SDS did not significantly differ from the population 
mean (Figure 3). The two patients with biallelic loss-of-function 
mutations of the KCNQ1 had normal birth lengths (−0.7 and 1.5 
SDS). Postnatal growth data were available only for one of them 
and this patient showed normal first year growth (length −0.2 
SDS at 1 year of age).
Other endocrine Features
As beta blocker treatment appeared to modulate intrauterine 
growth environment, we compared cord blood TSH levels 
(n = 41) between MI/BB+, MI/BB−, and PI groups. The mean 
cord blood TSH level in MI/BB− group did not differ from the 
PI group [6.1 ± 2.3 vs. 8.3 ± 4.7 mU/L, P = NS (0.07)]. The lowest 
mean level was found in the MI/BB+ and the highest mean level 
FigUre 3 | Individual childhood height standard deviation score curves of patients with long QT syndrome 1 due to loss-of-function mutations in KCNQ1.
5
Huttunen et al. LQT1 and Growth
Frontiers in Endocrinology | www.frontiersin.org April 2018 | Volume 9 | Article 194
in the PI group (4.8 ± 1.6 vs. 8.3 ± 4.7 mU/L, P = 0.011). TSH 
and free T4 levels were measured in 33 (32%) and 24 (23%) LQT1 
patients during pediatric follow-up, respectively, and none of the 
patients were diagnosed with hypo- or hyperthyroidism (data 
not shown). Insulin-like growth factor I levels were available 
only from four patients (3.8%) and they were within age- or bone 
age adjusted reference range. None of the patients received any 
treatment for endocrine diseases during childhood.
DiscUssiOn
The current work was sparked by our recent finding which showed 
that two specific mutations in KCNQ1, p.(Arg116Leu) and 
p.(Pro369Leu), underlie growth hormone deficiency and mater-
nally inherited gingival fibromatosis (4). KCNQ1 is expressed in 
mouse hypothalamic GHRH neurons, and also in pituitary soma-
totropes (4), lending credence to the hypothesis that KCNQ1 may 
act at different levels of the hypothalamic–pituitary axis. KCNQ1 
can associate with one of the five KCNE beta subunits that are 
known to modulate the potassium channel function. KCNE1 is 
important in the heart, whereas KCNE2 is ubiquitously expressed 
in different tissues (23). Recently, KCNQ1–KCNE2 complexes 
were suggested to participate in the regulation of myoinositol 
transport in the choroid plexus, secretion of insulin, and recently 
we found that KCNQ1 is implicated in cellular processes, such as 
spliceosomal snRNP assembly, nuclear import, and intracellular 
vesicle trafficking (4, 24, 25). The concept of KCNQ1 having a 
role beyond the regulation of cardiac repolarization is further 
enforced by the finding that KCNQ1 is implicated in the regula-
tion of beta-catenin signaling in colon cancer (26). We examined 
endocrine phenotypic features in a large cohort of pediatric 
patients with loss-of-function mutations in this gene. Our results, 
however, do not demonstrate clinically relevant associations 
between the loss-of-function KCNQ1 mutations and early growth 
or the endocrine system. These findings suggest that the role of 
KCNQ1 in the maintenance of the hypothalamic–pituitary axis 
integrity is not necessarily associated with the electrical activity 
of the KCNQ1–KCNE channels, and underscore the fact that 
to date only the codons 116 and 369 link KCNQ1 to pituitary 
hormone deficiency (4). To our knowledge, mutations in these 
codons have not been reported in patients with LQT1, and rare 
amino acid-changing variants are not reported in codons 116 
or 369 of KCNQ1 in Genome Aggregation Database (gnomAD 
r2.0.2)1 or Exome Aggregation Consortium database (ExAC vs. 
0.3.1).2 Similarly, aberrations in growth or pituitary dysfunction 
have not been described in patients with the extremely rare short 
QT syndrome (27, 28), or familial atrial fibrilliation (29) due to 
activating KCNQ1 mutations, which also corroborates that the 
electrical activity of KCNQ1–KCNE channels may not be the 
primary mechanism underlying the KCNQ1-related pituitary 
dysfynction (4). A clear limitation of our study is, however, 
paucity of IGF-I levels and other endocrine data.
We found that LQT1 patients exposed to maternal beta 
blocker medication during pregnancy were smaller at birth than 
those with paternally inherited mutations, and showed subse-
quent catch-up growth during the first year of life. Although 
impaired potassium channel function has been proposed to 
cause intrauterine growth restriction (30), loss-of-function 
mutations in KCNQ1 may not account for this phenotype. 
Instead, beta blocker use has been previously associated to 
reduced birth weight in preeclampsia (31–33). Interestingly, 
ablation of Kcne2 causes hypothyroidism in pregnant and 
lactating mice and in their pups (34), yet we did not find any 
enrichment of thyroid problems in our pediatric LQT1 patient 
series. Maternal beta blocker use, rather than the parental origin 
of the KCNQ1 mutation, was also associated with lower cord 
1 http://gnomad.broadinstitute.org/ (Accessed: April 14, 2018).
2 http://exac.broadinstitute.org/ (Accessed: April 14, 2018).
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TSH levels. To our knowledge, however, beta blocker use during 
pregnancy has not been reported to modulate offspring thyroid 
function. On the other hand, cord blood TSH levels are known 
to be affected by stress-related factors (35), and it is tempting 
to hypothesize that the effects of such factors on cord blood 
TSH levels are modified by maternal beta blocker use during the 
pregnancy. We did not investigate the incidence of disturbances 
in the glucose homeostasis in our patient cohort, since the 
frequency of hypoglycemia in Finnish children with LQT1 was 
very recently reported (36).
In conclusion, loss-of-function mutations in KCNQ1 have no 
apparent effects on growth, suggesting that impaired electrical 
activity of KCNQ1-KCNE channels may not alter growth hor-
mone secretion in a clinically significant manner. Our analyses 
show, however, that maternal beta blocker use during pregnancy 
seems to restrict prenatal growth with subsequent and rapid 
catch-up during the first year of life.
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